Lexicon Pharmaceuticals (LXRX) news

Lexicon Pharmaceuticals eligible for up to $1 bln in upfront and milestone payments plus royalties

Lexicon Pharmaceuticals earns third $10 million milestone payment from Novo Nordisk following achievement of key Phase 1 development milestone for LX9851

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has received a third $10 million milestone payment from Novo Nordisk A/S following the achievement of a key development milestone in the Phase 1 clinical trial of LX9851, a first-in-class oral non-incretin candidate for the treatment of obesity and…

Lexicon Pharmaceuticals - to offer up to 1,257,856 shares of common stock issuable to selling stockholders - SEC filing

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has filed with the U.S. Securities and Exchange Commission (SEC) to register up to 1,257,856 shares of its common stock for resale by selling stockholders. The filing, which is part of the company’s ongoing efforts to provide transparency and liquidity…

Lexicon Pharma 2Q R&D expenses $17.4M, est. $15.8M

Lexicon Pharmaceuticals (Nasdaq: LXRX) reported second-quarter 2025 research and development (R&D) expenses of $17.4 million, slightly exceeding the estimated range of $15.8 million. The increase was primarily attributed to higher investment in the SONATA Phase 3 clinical trial for sotagliflozin in…

Lexicon Pharmaceuticals - topline results for Sonata-HCM trial anticipated in Q1 2027